1/11
Looks like no tags are added yet.
Systemic Anti-Cancer Therapy.
cytotoxic chemotherapy, monoclonal antibodies, immunotherapies, tyrosine kinase inhibitors etc.
FBC identifies blood-cell suppression and infection or bleeding risk.
Renal and liver tests assess organ function that may affect drug clearance, toxicity and the need to adjust or delay treatment.
Many cytotoxic drugs are dosed using body surface area, so calculations must be accurate.
Previous toxicities may require treatment delay, dose reduction or a change in regimen.
Adjuvant treatment is given after a main treatment, such as surgery, to reduce recurrence risk.
Neoadjuvant treatment is given before the main treatment, often to shrink or control the tumour.
What do CTCAE (COMMON Terminology Criteria for Adverse Events) grades 1 to 5 mean?
Grade 1 is mild
grade 2 is moderate
grade 3 is severe or medically significant
grade 4 is life-threatening
grade 5 is death related to the adverse event
What are common toxicities of SACT?
Nausea and vomiting, diarrhoea, peripheral neuropathy, mucositis, alopecia, fatigue, myelosuppression etc.
Chemotherapy can reduce neutrophil counts, weakening the body's ability to fight infection.
Infection may then progress rapidly to sepsis, a medical emergency
A conditioned response in which a patient experiences nausea or vomiting before treatment because they associate chemotherapy with previous unpleasant experiences.
Which antiemetic classes and examples?
5-HT3 antagonists e.g. ondansetron
constipation S/E
corticosteroids e.g dexamethasone
only good if prophylaxis, useless if used once vomiting has begun
dopamine antagonists e.g. metoclopramide
avoid in parkinsons, but otherwise 1st line
antihistamines such as cyclizine
and multi-receptor drugs such as olanzapine and levomepromazine.
Why is QT prolongation important when choosing antiemetics?
Some antiemetics prolong the QT interval and increase arrhythmia risk.
metoclopramide, levomopromazine, domperidone, and ondansetron
What is G-CSF, what does it do, and why is it used during cancer treatment?
Granulocyte Colony-Stimulating Factor
stimulates the bone marrow to produce and release neutrophils.
used to reduce the risk of chemotherapy-associated severe neutropenia and febrile neutropenia.
Benefits = convenience, fewer hospital visits and greater patient control.
Risks = incorrect dosing, non-adherence, interactions and delayed recognition of toxicity
counselling and monitoring are essential.